Skip to content

Dianthus Therapeutics DNTH Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding

Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$0
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$0
Biogen logo
BiogenBIIB
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$4.51B+662%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Dianthus Therapeutics's preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding?
Dianthus Therapeutics (DNTH) reported preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding of $0 in Q1 2026.
What does preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding mean?
This represents the par value of preferred shares issued by the company, which carry specific rights and preferences over common stock, such as priority in dividend payments or liquidation. Preferred stock is a form of hybrid capital that sits between debt and common equity. If no shares are issued, this value remains at zero.